Pharmaceutical agents, compositions, and methods relating thereto
The present disclosure provides compounds of formulas (1)-(3), and compositions and methods of use thereof. The present disclosure also provides methods of preparing a provided compound and composition, and methods of characterizing a provided compound and composition.
1. A compound of formula (1):
or a pharmaceutically acceptable salt, ester, or isomer thereof, wherein
each of R 2 and R 3 is independently H or —C(O)—R, wherein each R is independently C 1-6 alkyl or 3-8 membered carbocyclic or heterocyclic, wherein R 2 and R 3 cannot be both H;
or R 2 together with R 3 form —(CH 2 ) n —C(O)—(CH 2 ) m —, wherein each of n and m is independently 0-3, and n+m≤3;
R 5 is —C 1-6 alkyl or —C 1-6 alkyl-CH(NH 2 )COOH;
R 8 is H or halogen; and
X is H or halogen,
wherein each of the carbocyclic, heterocyclic, —(CH 2 ) n —, and —(CH 2 ) m — moieties, independently, may optionally be substituted 1-3 times by —OH, halogen, NH 2 , CN, or C 1-6 alkyl; and
each C 1-6 alkyl moiety, independently, may optionally be substituted 1-3 times by —OH, halogen, NH 2 , or CN.
2. The compound of claim 1 , wherein R 8 is H.
3. The compound of claim 1 , wherein X is H.
4. The compound of claim 1 , wherein R 5 is —C 1-6 alkyl, which may optionally be substituted 1-3 times by —OH, halogen, NH 2 , or CN.
5. The compound of claim 4 , wherein R 5 is unsubstituted —C 1-6 alkyl.
6. The compound of claim 5 , wherein R 5 is methyl.
7. The compound of claim 1 , wherein R 5 is —C 1-6 alkyl-CH(NH 2 )COOH, wherein C 1-6 alkyl may optionally be substituted 1-3 times by —OH, halogen, NH 2 , or CN.
8. The compound of claim 7 , wherein R 5 is —C 1-6 alkyl-CH(NH 2 )COOH, wherein C 1-6 alkyl is unsubstituted.
9. The compound of claim 8 , wherein R 5 is —CH 2 CH 2 —CH(NH 2 )COOH.
10. The compound of claim 1 , wherein R 2 is H, and R 3 is —C(O)—R, wherein R is C 1-6 alkyl or 3-8 membered carbocyclic or heterocyclic, wherein each of the carbocyclic and heterocyclic moieties, independently, may optionally be substituted 1-3 times by —OH, halogen, NH 2 , CN, or C 1-6 alkyl; and each C 1-6 alkyl, independently, may optionally be substituted 1-3 times by —OH, halogen, NH 2 , or CN.
11. The compound of claim 1 , wherein R 3 is H, and R 2 is —C(O)—R, wherein R is C 1-6 alkyl or 3-8 membered carbocyclic or heterocyclic, wherein each of the carbocyclic and heterocyclic moieties, independently, may optionally be substituted 1-3 times by —OH, halogen, NH 2 , CN, or C 1-6 alkyl; and each C 1-6 alkyl, independently, may optionally be substituted 1-3 times by —OH, halogen, NH 2 , or CN.
12. The compound of claim 1 , wherein R is 3-8 membered carbocyclic or heterocyclic, wherein each of the carbocyclic and heterocyclic moieties, independently, may optionally be substituted 1-3 times by —OH, halogen, NH 2 , CN, or C 1-6 alkyl; and each C 1-6 alkyl, independently, may optionally be substituted 1-3 times by —OH, halogen, NH 2 , or CN.
13. The compound of claim 12 , wherein R is 3-8 membered unsubstituted carbocyclic or unsubstituted heterocyclic.
14. The compound of claim 13 , wherein R is 6 membered unsubstituted carbocyclic or unsubstituted heterocyclic.
15. The compound of claim 14 , wherein R is unsubstituted heterocyclic.
16. The compound of claim 15 , wherein R is
17. The compound of claim 16 , wherein the compound is of formula:
18. The compound of claim 1 , wherein each of R 2 and R 3 is independently C(O)—R, wherein each R is independently C 1-6 alkyl or 3-8 membered carbocyclic or heterocyclic, wherein each of the carbocyclic and heterocyclic moieties, independently, may optionally be substituted 1-3 times by —OH, halogen, NH 2 , CN, or C 1-6 alkyl; and each C 1-6 alkyl, independently, may optionally be substituted 1-3 times by —OH, halogen, NH 2 , or CN.
19. The compound of claim 18 , wherein each R is independently C 1-6 alkyl, which may optionally be substituted 1-3 times by —OH, halogen, NH 2 , or CN.
20. The compound of claim 19 , wherein each R is independently unsubstituted C 1-6 alkyl.
21. The compound of claim 20 , wherein the compound is of the formula:
22. The compound of claim 20 , wherein R is CH 3 .
23. The compound of claim 22 , wherein the compound is of the formula:
24. The compound of claim 1 , wherein R 2 together with R 3 form —(CH 2 ) n —C(O)—(CH 2 ) m —, wherein each of n and m is independently 0-3, and n+m≤3, wherein each of the —(CH 2 ) n — and —(CH 2 ) m — moieties, independently, may optionally be substituted 1-3 times by —OH, halogen, NH 2 , CN, or C 1-6 alkyl; and each C 1-6 alkyl, independently, may optionally be substituted 1-3 times by —OH, halogen, NH 2 , or CN.
25. The compound of claim 24 , wherein the —(CH 2 ) n — and —(CH 2 ) m — moieties are unsubstituted.
26. The compound of claim 24 , wherein n=m=0.
27. The compound of claim 26 , wherein the compound is of the formula:
28. The compound of claim 1 , or a pharmaceutically acceptable salt, ester, or isomer thereof, wherein the compound is of formula (2):
wherein R 8 is H or halogen;
X is H or halogen;
each R 5 ′ is independently H or halogen; and
each R is independently C 1-6 alkyl, each of which, independently, may optionally be substituted 1-3 times by halogen.
29. The compound of claim 28 , wherein the compound is of formula (2′):
30. The compound of claim 28 , wherein R 8 is H.
31. The compound of claim 28 , wherein X is H.
32. The compound of claim 28 , wherein each R is independently unsubstituted C 1-6 alkyl.
33. The compound of claim 28 , wherein each R is independently C 1-3 alkyl, each of which, independently, may optionally be substituted 1-3 times by halogen.
34. The compound of claim 28 , wherein each R is independently unsubstituted C 1-3 alkyl.
35. The compound of claim 34 , wherein each R is independently —CH 3 , —CH 2 CH 3 , or —CH 2 CH 2 CH 3 .
36. The compound of claim 1 , or a pharmaceutically acceptable salt, ester, or isomer thereof, wherein the compound is of formula (3):
wherein R 8 is H or halogen;
X is H or halogen; and
each R′ is independently H or halogen.
37. The compound of claim 36 , wherein the compound is of formula (3′):
38. The compound of claim 36 , wherein R 8 is H.
39. The compound of claim 36 , wherein X is H.
40. The compound of claim 36 , wherein each C(R′) 3 is independently CF 3 , CHF 2 , or CH 2 F, or CH 3 .
41. The compound of claim 40 , wherein each C(R′) 3 is CH 3 .
42. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, ester, or isomer thereof.
43. The pharmaceutical composition of claim 42 , wherein the composition comprises only a single compound of formula (1), or a pharmaceutically acceptable salt, ester, or isomer thereof.
44. A method for treating an insulin resistance disorder comprising administering a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, ester, or isomer thereof.
45. The method of claim 44 , wherein the disorder is hyperglycemia, retinopathy, neuropathy, nephropathy, hyperinsulinemia, polycystic ovarian syndrome (PCOS), or a type II diabetes related vascular disorder.
46. The method of claim 44 , wherein the step of administering comprises administering a composition that comprises and/or delivers the compound, according to a regimen that achieves the administering of the therapeutically effective amount.
47. The method of claim 46 , wherein the composition is a pharmaceutical composition comprising an active pharmaceutical ingredient and one or more carriers or excipients, wherein the active pharmaceutical ingredient comprises or consists of the compound of formula I.
48. The method of claim 46 , wherein the active pharmaceutical ingredient consists of the compound.
49. A method for treating diabetes comprising administering a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, ester, or isomer thereof.
50. The method of claim 49 , wherein the diabetes is type I diabetes or type II diabetes.
51. A method for treating a degenerative disease selected from the group consisting of Alzheimer's disease, Parkinson's diseases, and sarcopenia, comprising administering a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, ester, or isomer thereof.
52. A method for inhibiting glucose production, comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt, ester, or isomer thereof.
53. A method for reducing serum HbA1c level, comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt, ester, or isomer thereof.
54. A method for increasing glucose tolerance, comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt, ester, or isomer thereof.
55. A method for inhibiting G6pc expression, comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt, ester, or isomer thereof.
56. A method for enhancing phosphorylation of Pdk1, Akt, AS160, and Foxo1 in the liver and/or in the skeletal muscle, comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt, ester, or isomer thereof.
57. A method for increasing Glut4 expression, comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt, ester, or isomer thereof.
58. A method for activating and/or restoring insulin signaling in a subject in insulin-resistant state, comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt, ester, or isomer thereof.
59. The method of claim 58 , wherein the subject is characterized by significant levels of circulating insulin.
60. The method of claim 58 , wherein the insulin-resistant state is characterized by a reduction in correctly or appropriate phosphorylated insulin receptor in the subject.
61. The method of claim 58 , wherein the subject has diabetes, and/or diabetes associated disease, disorders, or conditions.
62. A method for enhancing glucose uptake into cells in a subject, comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt, ester, or isomer thereof.
63. The method of claim 62 , wherein the cells are skeletal muscle cells and liver cells.
64. A method for enhancing translocation of glucose transporter proteins (GLUTs) from cytosolic vesicles to plasma membrane for glucose uptake, comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt, ester, or isomer thereof.